← Human Trials & Peer-Reviewed Studies
Assessment of local and systemic 25-hydroxy-vitamin D, RANKL, OPG, and TNF levels in patients with rheumatoid arthritis and periodontitis.
Plain-language guide to PMID 28904316 (2017): controlled clinical trial of Vitamin D, K2, Magnesium and Zinc in 17 patients, rheumatoid arthritis.
Key Facts
- PMID
- 28904316
- Journal
- Journal of oral science
- Year
- 2017
- Study type
- Controlled Clinical Trial
- Authors
- Balci Yuce H et al. (6 authors)
- DOI
- 10.2334/josnusd.16-0677
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial looks at Vitamin D, K2, Magnesium and Zinc in the context of rheumatoid arthritis.
The present study aimed to evaluate proinflammatory cytokine and vitamin D levels in rheumatoid arthritis (RA) and chronic periodontitis (CP) patients and healthy individuals before and after initial periodontal treatment.
Why It Was Studied
Clinical periodontal measurements were recorded and gingival crevicular fluid (GCF) and blood samples were recorded.
RA + CP and CP patients received nonsurgical periodontal treatment.
Who Took Part
According to the abstract, 17 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
Overall, 17 CP patients with RA (RA + CP), 18 systemically healthy CP patients (CP), and 18 healthy controls (C) were included.
What Was Measured
Clinical periodontal measurements were recorded and gingival crevicular fluid (GCF) and blood samples were recorded.
Vitamin D, tumor necrosis factor (TNF)-α, receptor activator of nuclear factor-KB ligand (RANKL), and OPG levels were determined in GCF and serum.
The subject headings attached to it are Arthritis, Rheumatoid, Case-Control Studies, Gingival Crevicular Fluid, Osteoprotegerin, Periodontitis, RANK Ligand and Tumor Necrosis Factor-alpha.
The authors tagged it with the keywords RANKL/OPG, chronic periodontitis, rheumatoid arthritis and vitamin D.
What This Means in Plain Language
This is a controlled clinical trial of Vitamin D, K2, Magnesium and Zinc in 17 patients in people with rheumatoid arthritis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2017 (Journal of oral science), a journal based in Japan.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Rheumatoid arthritis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.